AR117206A1 - Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer - Google Patents
Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncerInfo
- Publication number
- AR117206A1 AR117206A1 ARP190103484A ARP190103484A AR117206A1 AR 117206 A1 AR117206 A1 AR 117206A1 AR P190103484 A ARP190103484 A AR P190103484A AR P190103484 A ARP190103484 A AR P190103484A AR 117206 A1 AR117206 A1 AR 117206A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- group
- independently selected
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Compuestos derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido como miméticos de SMAC que activan la vía de ncNF-kB, una composición farmacéutica que los comprende y el uso de los mismos para el tratamiento de una infección por VIH y para la terapia del cáncer y de síndromes precancerosos. Reivindicación 1: Un compuesto representado por la fórmula (1), una sal farmacéuticamente del mismo o un estereoisómero del mismo, en el que: R, R, R y R se seleccionan independientemente entre H y CH₃; X¹ y X² se seleccionan independientemente entre el grupo que consiste en O y S; y L es un enlazador seleccionado entre el grupo que consiste en: (i) un compuesto de fórmula (2); (ii) un compuesto de fórmula (3); (iii) un compuesto de fórmula (4); (iv) un compuesto de fórmula (5); (v) un compuesto de fórmula (6); (vi) un compuesto de fórmula (7); (vii) un compuesto de fórmula (8); (viii) un compuesto de fórmula (9); (ix) un compuesto de fórmula (10); (x) un compuesto de fórmula (11); (xi) un compuesto de fórmula (12); y (xii) un compuesto de fórmula (13), en los que: Ar¹, Ar², Ar³, Ar⁴, Ar⁵, Ar⁶, Ar⁷, Ar⁸, Ar⁹, Ar¹⁰, Ar¹¹, Ar¹², Ar¹³, Ar¹⁴, Ar¹⁵, Ar¹⁶, Ar¹⁷, Ar¹⁸, Ar¹⁹, Ar²¹, Ar²², Ar²³, Ar²⁴, Ar²⁵ y Ar²⁶ se seleccionan cada uno independientemente de arilo C₆₋₁₄; Alk, Alk² y Alk³ se seleccionan cada uno independientemente entre: los compuestos de fórmula (14) y (15); R¹, es cicloalquilo C₃₋₆ o heterociclo C₁₋₆; R² se selecciona entre el grupo que consiste en -(CH₂)ₐ-, -(CH₂)ᵇ-O-(CH₂)ᶜ-, -(CH₂)ᵈ-aril C₆₋₁₄-(CH₂)ₑ- y -(CH₂)ᶠ-heteroaril C₁₋₆-(CH₂)ᵍ-; R³ se selecciona entre el grupo que consiste en -(CH₂)ₕ-; -(CH₂)ⁱ-O-(CH₂)ʲ-, -(CH₂)ₖ-aril C₆₋₁₄-(CH₂)ₗ- y -(CH₂)ₘ-heteroaril C₁₋₆-(CH₂)ₘ-; R⁴ es cicloalquilo C₃₋₆, arilo C₆₋₁₄ o (CH₂)ₙ-aril C₆₋₁₄-(CH₂)ₙ-, (CH₂)ₙ-Alk-(CH₂)ₙ-, en donde n, n, n y n se seleccionan independientemente de 1 a 8; R⁵ es cicloalquilo C₃₋₆; R⁶ se selecciona del el grupo que consiste en (CH₂)ᶻ o un compuesto del grupo de fórmulas (16); a, b, c, d, e, f, g, h, i, j, k, I, m, m, m, n, p, q, r, s, t, u, v, x, y y z se seleccionan cada uno independientemente de 1 a 12.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773563P | 2018-11-30 | 2018-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117206A1 true AR117206A1 (es) | 2021-07-21 |
Family
ID=68808475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103484A AR117206A1 (es) | 2018-11-30 | 2019-11-28 | Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP3886987B1 (es) |
| JP (2) | JP7406556B2 (es) |
| KR (1) | KR20210097154A (es) |
| CN (1) | CN113613724B (es) |
| AR (1) | AR117206A1 (es) |
| AU (1) | AU2019390729B2 (es) |
| BR (1) | BR112021010353A2 (es) |
| CA (1) | CA3121140A1 (es) |
| CL (1) | CL2021001388A1 (es) |
| ES (1) | ES2968538T3 (es) |
| IL (2) | IL283487B2 (es) |
| MX (2) | MX2021006156A (es) |
| MY (1) | MY202884A (es) |
| TW (2) | TW202428584A (es) |
| WO (1) | WO2020110056A1 (es) |
| ZA (1) | ZA202103349B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| JP7044375B2 (ja) | 2016-05-31 | 2022-03-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｐｔｐｎ１１の複素環式阻害剤 |
| IL278297B2 (en) | 2018-05-02 | 2023-12-01 | Navire Pharma Inc | Substituted heterocyclic inhibitors of ptpn11 |
| PL3833670T3 (pl) | 2018-08-10 | 2024-08-19 | Navire Pharma, Inc. | Pochodne 6-(4-amino-3-metylo-2-oksa-8-azaspiro[4.5]dekan-8-ylo)-3-(2,3-dichlorofenylo)-2-metylopirymidyn-4(3h)-onu oraz powiązane związki jako inhibitory ptpn11 (shp2) do leczenia raka |
| IL283487B2 (en) * | 2018-11-30 | 2024-07-01 | Glaxosmithkline Ip Dev Ltd | Compounds useful in hiv therapy |
| WO2020113209A1 (en) | 2018-11-30 | 2020-06-04 | Comet Therapeutics, Inc. | Pantetheine derivatives and uses thereof |
| US20230115837A1 (en) * | 2019-11-08 | 2023-04-13 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (iap) protein antagonists |
| WO2022204084A1 (en) * | 2021-03-23 | 2022-09-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for inhibiting formation of the hiv latent reservoir |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| KR20020047132A (ko) | 1999-08-24 | 2002-06-21 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
| CZ304059B6 (cs) | 2000-12-21 | 2013-09-11 | Glaxo Group Limited | Deriváty pyrimidinu a farmaceutický prostredek |
| CN1533390A (zh) | 2001-03-19 | 2004-09-29 | СҰҩƷ��ҵ��ʽ���� | 包含三氮杂螺[5.5]十一烷衍生物作为活性成分的药物组合物 |
| WO2004004771A1 (ja) | 2002-07-03 | 2004-01-15 | Ono Pharmaceutical Co., Ltd. | 免疫賦活組成物 |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| JP4532409B2 (ja) | 2003-01-23 | 2010-08-25 | 小野薬品工業株式会社 | ヒトｐｄ−１に対し特異性を有する物質 |
| JP4674231B2 (ja) * | 2004-03-01 | 2011-04-20 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | ２量体小分子アポトーシス増強剤 |
| US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| PL2298768T3 (pl) | 2004-06-11 | 2013-03-29 | Japan Tobacco Inc | Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| KR101071516B1 (ko) * | 2006-05-05 | 2011-10-10 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 2가 ｓｍａｃ 모방체 및 그의 용도 |
| US8202902B2 (en) * | 2006-05-05 | 2012-06-19 | The Regents Of The University Of Michigan | Bivalent SMAC mimetics and the uses thereof |
| CN201013021Y (zh) | 2006-11-24 | 2008-01-30 | 李一君 | 排水器改进结构 |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| EP2058312A1 (en) * | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201170375A1 (ru) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
| JP6087503B2 (ja) | 2008-09-26 | 2017-03-08 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途 |
| SMT202500126T1 (it) | 2008-12-09 | 2025-05-12 | Hoffmann La Roche | Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t |
| US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| US8815927B2 (en) * | 2009-10-23 | 2014-08-26 | The Regents Of The University Of Michigan | Bivalent diazo bicyclic Smac mimetics and the uses thereof |
| WO2011059763A2 (en) * | 2009-10-28 | 2011-05-19 | Joyant Pharmaceuticals, Inc. | Dimeric smac mimetics |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| HRP20171653T1 (hr) | 2009-11-24 | 2017-12-15 | Medimmune Limited | Vezna sredstva koja služe ciljano protiv b7-h1 |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| WO2013124701A2 (en) * | 2012-02-20 | 2013-08-29 | Universita' Degli Studi Di Milano | New homo- and heterodimeric smac mimetic compounds as apoptosis inducers |
| EA037351B8 (ru) | 2012-05-15 | 2021-04-29 | Бристол-Майерс Сквибб Компани | Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4 |
| CN104994873B (zh) | 2012-10-04 | 2017-12-22 | 达纳－法伯癌症研究所公司 | 人单克隆抗‑pd‑l1抗体和使用方法 |
| CA2896577C (en) * | 2012-11-30 | 2024-01-23 | Sanford-Burnham Medical Research Institute | Inhibitor of apoptosis protein (iap) antagonists |
| EP3151920B1 (en) * | 2014-06-04 | 2025-08-06 | Sanford-Burnham Medical Research Institute | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy |
| IL283487B2 (en) * | 2018-11-30 | 2024-07-01 | Glaxosmithkline Ip Dev Ltd | Compounds useful in hiv therapy |
| US20230115837A1 (en) * | 2019-11-08 | 2023-04-13 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (iap) protein antagonists |
-
2019
- 2019-11-28 IL IL283487A patent/IL283487B2/en unknown
- 2019-11-28 CN CN201980090907.2A patent/CN113613724B/zh active Active
- 2019-11-28 AU AU2019390729A patent/AU2019390729B2/en active Active
- 2019-11-28 TW TW112144745A patent/TW202428584A/zh unknown
- 2019-11-28 BR BR112021010353-8A patent/BR112021010353A2/pt unknown
- 2019-11-28 JP JP2021531316A patent/JP7406556B2/ja active Active
- 2019-11-28 EP EP19816924.5A patent/EP3886987B1/en active Active
- 2019-11-28 WO PCT/IB2019/060267 patent/WO2020110056A1/en not_active Ceased
- 2019-11-28 KR KR1020217019819A patent/KR20210097154A/ko active Pending
- 2019-11-28 EP EP23206927.8A patent/EP4342473A3/en not_active Withdrawn
- 2019-11-28 MX MX2021006156A patent/MX2021006156A/es unknown
- 2019-11-28 TW TW108143509A patent/TWI824069B/zh active
- 2019-11-28 CA CA3121140A patent/CA3121140A1/en active Pending
- 2019-11-28 MY MYPI2021002756A patent/MY202884A/en unknown
- 2019-11-28 IL IL310831A patent/IL310831A/en unknown
- 2019-11-28 AR ARP190103484A patent/AR117206A1/es unknown
- 2019-11-28 ES ES19816924T patent/ES2968538T3/es active Active
-
2021
- 2021-05-18 ZA ZA2021/03349A patent/ZA202103349B/en unknown
- 2021-05-26 MX MX2023014492A patent/MX2023014492A/es unknown
- 2021-05-27 CL CL2021001388A patent/CL2021001388A1/es unknown
-
2023
- 2023-11-09 JP JP2023191205A patent/JP2024023259A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019390729B2 (en) | 2022-08-11 |
| MY202884A (en) | 2024-05-28 |
| CN113613724A (zh) | 2021-11-05 |
| JP7406556B2 (ja) | 2023-12-27 |
| MX2021006156A (es) | 2021-09-08 |
| BR112021010353A2 (pt) | 2021-08-31 |
| IL283487B1 (en) | 2024-03-01 |
| ZA202103349B (en) | 2022-12-21 |
| AU2019390729A1 (en) | 2021-06-03 |
| ES2968538T3 (es) | 2024-05-10 |
| EP3886987A1 (en) | 2021-10-06 |
| JP2022509869A (ja) | 2022-01-24 |
| CN113613724B (zh) | 2024-11-08 |
| WO2020110056A1 (en) | 2020-06-04 |
| IL283487A (en) | 2021-07-29 |
| IL283487B2 (en) | 2024-07-01 |
| MX2023014492A (es) | 2024-01-25 |
| EP4342473A2 (en) | 2024-03-27 |
| TWI824069B (zh) | 2023-12-01 |
| TW202428584A (zh) | 2024-07-16 |
| KR20210097154A (ko) | 2021-08-06 |
| EP4342473A3 (en) | 2024-05-15 |
| CL2021001388A1 (es) | 2021-11-05 |
| IL310831A (en) | 2024-04-01 |
| JP2024023259A (ja) | 2024-02-21 |
| EP3886987B1 (en) | 2023-11-15 |
| EP3886987C0 (en) | 2023-11-15 |
| TW202039514A (zh) | 2020-11-01 |
| CA3121140A1 (en) | 2020-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117206A1 (es) | Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer | |
| CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
| MX2020008754A (es) | Compuestos farmaceuticos. | |
| AR120700A1 (es) | Inhibidores de kras g12c | |
| CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
| CO2019011762A2 (es) | Compuestos que inhiben la proteína mcl-1 | |
| UY38483A (es) | Heterociclos funcionalizados como agentes antivirales | |
| AR114971A1 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| AR119018A1 (es) | Inhibidores de proteína quinasas dependientes de adn | |
| AR103251A1 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| PE20190326A1 (es) | Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas | |
| AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
| AR095019A1 (es) | Derivados de amatoxina | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| BR112018007772A2 (pt) | compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer | |
| AR108906A1 (es) | Heterociclos de biarilmetilo | |
| AR107170A1 (es) | Compuestos heterocíclicos tricíclicos condesados como inhibidores de integrasa del vih | |
| MX2023011715A (es) | Compuestos de oxoisoindolina sustituidos con piridinilo. | |
| AR114369A1 (es) | Dinucleótidos cíclicos como agentes antineoplásicos | |
| AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
| AR119910A1 (es) | DERIVADOS DE 4,4a,5,7,8,8a-HEXAHIDROPIRIDO[4,3-b][1,4]OXAZIN-3-ONA COMO INHIBIDORES DE MAGL | |
| CY1123955T1 (el) | [8-(φαινυλοσουλφονυλο)-3,8-διαζαδικυκλο[3.2.1]οκτ-3-υλο](1η-1,2,3-τριαζολο-4-υλο)μεθανονες | |
| AR109952A1 (es) | Derivados de fenilamina 4-sustituidos y su uso para proteger cultivos al combatir microorganismos fitopatogénicos indeseados | |
| AR103156A1 (es) | Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos | |
| AR127431A1 (es) | Compuestos novedosos |